124 related articles for article (PubMed ID: 9410074)
21. Meropenem versus imipenem/cilastatin in the treatment of sepsis in Chinese patients.
Kuo BI; Fung CP; Liu CY
Zhonghua Yi Xue Za Zhi (Taipei); 2000 May; 63(5):361-7. PubMed ID: 10862445
[TBL] [Abstract][Full Text] [Related]
22. Changing role of carbapenems in the treatment of lower respiratory tract infections.
Lode H; Hamacher J; Eller J; Schaberg T
Scand J Infect Dis Suppl; 1995; 96():17-23. PubMed ID: 7652498
[TBL] [Abstract][Full Text] [Related]
23. Neurological complication during imipenem/cilastatin therapy in uraemic patients.
Campise M
Nephrol Dial Transplant; 1998 Jul; 13(7):1895-6. PubMed ID: 9681765
[No Abstract] [Full Text] [Related]
24. Correlation between in vitro and in vivo models of proconvulsive activity with the carbapenem antibiotics, biapenem, imipenem/cilastatin and meropenem.
Day IP; Goudie J; Nishiki K; Williams PD
Toxicol Lett; 1995 Apr; 76(3):239-43. PubMed ID: 7762010
[TBL] [Abstract][Full Text] [Related]
25. Serum bactericidal activities and comparative pharmacokinetics of meropenem and imipenem-cilastatin.
Dreetz M; Hamacher J; Eller J; Borner K; Koeppe P; Schaberg T; Lode H
Antimicrob Agents Chemother; 1996 Jan; 40(1):105-9. PubMed ID: 8787889
[TBL] [Abstract][Full Text] [Related]
26. [Meropenem (Merrem) vs imipenem/cilastatin in hospital treatment of intra-abdominal infections. A multicenter study].
Tonelli F
Minerva Chir; 1997 Mar; 52(3):317-26. PubMed ID: 9148225
[TBL] [Abstract][Full Text] [Related]
27. Comparison of 30-min and 3-h infusion regimens for imipenem/cilastatin and for meropenem evaluated by Monte Carlo simulation.
Lee LS; Kinzig-Schippers M; Nafziger AN; Ma L; Sörgel F; Jones RN; Drusano GL; Bertino JS
Diagn Microbiol Infect Dis; 2010 Nov; 68(3):251-8. PubMed ID: 20851549
[TBL] [Abstract][Full Text] [Related]
28. Comparison of in vivo nephrotoxicity in the rabbit by a pyrrolidinyl-thio Carbapenem CW-270031.
Kim JM; Ha JR; Oh SW; Kim HG; Lee JM; Kim BO; Lee DG; Lee SH; Kim JG
J Microbiol Biotechnol; 2008 Nov; 18(11):1768-72. PubMed ID: 19047819
[TBL] [Abstract][Full Text] [Related]
29. [Multicenter comparative study of meropenem vs. imipenem in the intramuscular treatment of hospital infections of the urinary tract].
Tallarigo C; Comunale L; Baldassarre R; Poletti G
Minerva Urol Nefrol; 1995 Sep; 47(3):147-56. PubMed ID: 8815553
[TBL] [Abstract][Full Text] [Related]
30. The risk of seizures among the carbapenems: a meta-analysis.
Cannon JP; Lee TA; Clark NM; Setlak P; Grim SA
J Antimicrob Chemother; 2014 Aug; 69(8):2043-55. PubMed ID: 24744302
[TBL] [Abstract][Full Text] [Related]
31. Imipenem/cilastatin (1.5 g daily) versus meropenem (3.0 g daily) in patients with intra-abdominal infections: results of a prospective, randomized, multicentre trial.
Basoli A; Meli EZ; Mazzocchi P; Speranza V
Scand J Infect Dis; 1997; 29(5):503-8. PubMed ID: 9435041
[TBL] [Abstract][Full Text] [Related]
32. [A clinical phase I study on intramuscular imipenem/cilastatin sodium].
Onishi A; Otawa M; Hara K
Jpn J Antibiot; 1991 Aug; 44(8):860-76. PubMed ID: 1920812
[TBL] [Abstract][Full Text] [Related]
33. Formulary review of the carbapenems: comparison of imipenem/cilastatin and meropenem.
Richerson MA; Ambrose PG; Quintiliani R; Nightingale CH
Conn Med; 1998 Mar; 62(3):165-9. PubMed ID: 9573653
[TBL] [Abstract][Full Text] [Related]
34. Safety of imipenem/cilastatin in neurocritical care patients.
Hoffman J; Trimble J; Brophy GM
Neurocrit Care; 2009; 10(3):403-7. PubMed ID: 19116700
[TBL] [Abstract][Full Text] [Related]
35. Lack of cross-reactivity to meropenem in a patient with an allergy to imipenem-cilastatin.
Bauer SL; Wall GC; Skoglund KJ; Peters LK
J Allergy Clin Immunol; 2004 Jan; 113(1):173-5. PubMed ID: 14713926
[No Abstract] [Full Text] [Related]
36. Safe use of meropenem in a patient with a possible nonimmediate allergy to imipenem.
Lakhal K; Lortat-Jacob B; Neukirch C; Pajot O; Wolff M
Pharmacotherapy; 2007 Sep; 27(9):1334-8. PubMed ID: 17723087
[TBL] [Abstract][Full Text] [Related]
37. How should imipenem-cilastatin be used in the treatment of fever and infection in neutropenic cancer patients?
Raad II; Abi-Said D; Rolston KV; Karl CL; Bodey GP
Cancer; 1998 Jun; 82(12):2449-58. PubMed ID: 9635539
[TBL] [Abstract][Full Text] [Related]
38. Cross-reactivity and tolerability of imipenem in patients with delayed-type, cell-mediated hypersensitivity to beta-lactams.
Schiavino D; Nucera E; Lombardo C; Decinti M; Pascolini L; Altomonte G; Buonomo A; Patriarca G
Allergy; 2009 Nov; 64(11):1644-8. PubMed ID: 19392998
[TBL] [Abstract][Full Text] [Related]
39. Safety profile of meropenem: an updated review of over 6,000 patients treated with meropenem.
Linden P
Drug Saf; 2007; 30(8):657-68. PubMed ID: 17696578
[TBL] [Abstract][Full Text] [Related]
40. Carbapenems.
Norrby SR
Med Clin North Am; 1995 Jul; 79(4):745-59. PubMed ID: 7791421
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
